TCTR20220907001SuspendedPhase 1
Bioequivalence Study of 50 mg Dolutegravir Film-coated Tablets in Healthy Thai Volunteers
nison Laboratories Co., Ltd.0 sites30 target enrollmentStarted: September 7, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Suspended
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 55 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Healthy Thai male or female volunteers aged between 18 and 55 years.
- •2. The Body Mass Index (BMI) ranges from 18.5 to 25 kg/m2.
- •3. Determined healthy by medical history, physical examination and vital signs
- •4. The results of the clinical laboratory tests are within clinically acceptance limits i.e., blood urea nitrogen (BUN), serum creatinine, AST, ALT, total bilirubin, alkaline phosphatase, GGT, blood potassium, sodium, calcium, chloride, fasting blood sugar and hematology examinations including differential blood counts and HBsAg test. Some of the clinical laboratory values that out of the normal range will be carefully considered by clinical investigator.
- •5. Negative pregnancy test for female volunteers and effective contraceptive must be used at least 14 days prior to the study initiation and not breast-feeding women.
- •6. Male volunteers who are surgically sterile or agree to use an effective contraception throughout the study.
- •7. Willing to participate in the study and signed the informed consent form.
Exclusion Criteria
- •1. History or evidence of allergy or hypersensitivity to dolutegravir sodium or any of the excipients of this product or any related drugs.
- •2. History or evidence of allergy or hypersensitivity to heparin.
- •3. History or evidence of hypertension (systolic BP 140 mmHg, diastolic BP 90 mmHg) or hypotension (systolic BP <90 mmHg, diastolic BP <60 mmHg).
- •4. History or evidence of gastrointestinal, hepatic, renal, cardiovascular, hemato-logical disease or allergic disease or bronchial asthma or any disease that may affect the bioavailability of drug.
- •5. Evidence of more than one abnormal ECG which is considered as clinically significant.
- •6. History of chronic or debilitating diseases.
- •7. Positive HBsAg tests.
- •8. History of alcoholism or drug abuse.
- •9. Positive urine drug abuse tests (Benzodiazepines, Methamphetamine and Opi-ates).
- •10. History of regular alcohol consumption (more than 1 time a week) or alcohol consumption within 7 days prior to the study drug administration and until the completion of the study.
- •11. History of smoking more than 10 cigarettes/day, or moderate smokers (less than 10 cigarettes/day) and could not quit at least 7 days prior to the study drug administration and until the completion of the study.
- •12. Tea/coffee or caffeine- or xanthine-containing beverage consumption within 7 days prior to the study drug administration and until the completion of the study.
- •13. Grapefruit juice or grapefruit-containing products consumption within 7 days prior to the study drug administration and until the completion of the study.
- •14. Use of any prescription drugs or over-the-counter (OTC) drugs or herbal medi-cines within 30 days or vitamins or food supplements within 14 days prior to the study drug administration or use hormonal methods of contraception with-in 28 days (discontinuation for at least 6 months is required for Depo-Provera use) prior to receiving the first dose of the study medication.
- •15. Blood donation or blood loss over 350 mL within 90 days before the study.
- •16. Participation in any clinical studies within 90 days before the study.
Investigators
Similar Trials
Not yet recruiting
Unknown
In vivo Bioequivalence study of Dolutegravir tabletsIRCT20220211053992N36Tabriz University of Medical Sciences24
Recruiting
Unknown
Bioequivalence study of Dulotegravir 50 mg tabletIRCT20200105046010N102Sobhan trading group24
Not yet recruiting
Unknown
Benefits and safety of major medicines in HIV patients.CTRI/2024/04/065522Institute of Medical Sciences, Banaras Hindu University
Completed
Unknown
Vigabatrin film coated tablet BioequivalenceBioequivalence study in healthy volunteers.IRCT20130313012810N32Modava Pharmaceutical Company24
Recruiting
Phase 2
Evaluation of the effect of an antiretroviral drug in patients infected with HTLV-1.Human T-lymphotropic virus 1B04RBR-5x7ccxpFundação Bahiana de Infectologia - FBA